Vertex Pharmaceuticals (NQ:VRTX)

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Topics Artificial Intelligence

3 large-cap stocks with solid fundamentals

October 30, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue ↗

After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

October 27, 2026

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.

I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move ↗

Topics Intellectual Property Lawsuit

October 26, 2026

Here's how I'm staying calm as valuations hit record highs.

The company's gene-editing-focused platform looks promising.

Topics Artificial Intelligence Economy

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More ↗

October 24, 2026

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. ↗

October 24, 2026

Vertex is expanding beyond its cystic fibrosis franchise.

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy...

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III ↗

October 23, 2026

Via MarketBeat

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

October 23, 2026

S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗

October 21, 2026

Via Chartmill

Topics Artificial Intelligence Stocks Supply Chain

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

Topics Intellectual Property

Vertex Appoints Daniel Brennan to its Board of Directors

October 20, 2026

Buffett has warned about "gambling" in the market.

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗

October 19, 2026

The company's expertise in gene editing could lead to more breakthroughs.

Topics Intellectual Property Retirement

Where Will CRISPR Therapeutics Stock Be in 2030? ↗

October 18, 2026

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗

October 18, 2026

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...

Topics ETFs

1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm

October 16, 2026

Vertex Pharmaceuticals is showing that it isn't a one-trick pony.

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders ↗

October 15, 2026

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 13, 2026

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

2 High-Flying Stocks on Our Watchlist and 1 We Question

October 12, 2026

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

October 09, 2026

Most of any gains (or lack thereof) from here will be driven by just three factors.

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗

October 09, 2026

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

October 07, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down

October 05, 2026

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

Topics Energy

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 04, 2026

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 01, 2026

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward...

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗

Topics Intellectual Property

September 29, 2026

This biotech player is firing on all cylinders.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Topics Intellectual Property

2 Healthcare Stocks to Target This Week and 1 We Avoid

September 28, 2026

And there could be more positive developments ahead.

2 Healthcare Stocks That Just Delivered Great News for Investors ↗

September 26, 2026

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

September 22, 2026